icon investor relations

These statements are based on management's current expectations and information currently available, including current economic and industry conditions. Eric White Coldwell -- Robert W. Baird -- Analyst. This calendar will be updated regularly. But the intelligence side of things is really using technology and data in a way that's perhaps a little bit more nuanced and a little bit more insightful than has been used in the past and allowing us to ultimately deliver trials in a different way, much more effectively and efficiently. ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the worlds first approved vaccine for COVID-19. ICON CARES is our commitment to making a positive impact on our people, environment and our community. Please ask your question. Adjusted net income attributable to the group for the quarter was $113.2 million, a margin of 13%, equating to diluted earnings per share of $2.12. We've certainly seen already some wins on the lab front and revenue starting to flow into and certainly in the second half of the year, we'll see revenue starting to flow from those immediate opportunities with services, imaging labs that's happening, we have an expectation of around $100 million in revenue synergies on a run rate -- annual run rate basis, and I think we're well on our way to that, and I'd like to think we can potentially exceed it. This calendar will be updated regularly. We've talked a lot about our oneview tool and how we're using that to identify the right sites and select sites, our patient approaches where we're going directly to patient and catering, that sort of data and wearables, it's a variety of things around our patient, site and data strategy. This press release contains forward-looking statements. It will have pass-throughs of course, but not nearly to the same extent as 44,000-patient trial or those. Waves $1.92-8.97%. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes. Full year 2023 revenue guidance reaffirmed in the range of $7,940 - $8,340 million, representing a year over year increase of 2.6% to 7.7%, and full year 2023 adjusted earnings per share. Jitter Cleaners/Network Synchronizers. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. Yes, Jack, I mean, we -- I mean, as I said probably previously, to -- our answer is we do expect the growth to continue to be sequential. I want to reiterate my continued appreciation for their dedication and commitment as we look forward to another year of strong progress during 2021.. Notice of an online live Investor Presentation - "AI's Game-Changing Impact on Drug Discovery" via Investor Meet Company. But the big -- those big pass-through studies, the big vaccine studies, those are probably coming toward the end of it now, which is sort of attenuating a little bit the very rapid growth in revenue we've seen over the last couple of quarters. I think we can handle that. My follow-up question kind of related to that, you mentioned in your prepared remarks also, you touched on a number of the areas where cross-selling is an opportunity. Kent Thoelke is our Chief Innovation Officer, has driven this, and he has driven a number of these sorts of initiatives. Steve, I'm going to follow up on that kind of last line of questioning. Current customers include three of the world's top 15 pharma companies since initial launch in May 2021. This resulted in net business wins of $3.8 billion and a book to bill of 1.38. Programmable OCXOs. ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world's leading Contract Research Organisations through a number of high-profile industry awards. This resulted in net business wins of $2,351 million and a book to bill of 1.21. 13 Jun 2023. This represents a year on year increase of 147.4% or 148.7% on a constant currency basis. May 2023 Investor Presentation. We kind of keep approaching the top, but we're not quite there, and I think it might be a few more months or even into the winter before we actually get there. Our mission is to help clients accelerate the development of Okay. Asia is not so much of an issue. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. This compares with 39 days at the end of March 2021 and 53 days at the end of June 2020. Site availability? That's kind of indicated in the guidance, certainly at the midpoint and the higher end even. Gross business wins were $4.6 billion and cancellations were $725 million. And on our backlog, it's in the high mid-single digits. The environment created by the COVID-19 pandemic has presented the industry with an opportunity to accelerate changes in the clinical monitoring process. I would now like to hand over the call to our CFO, Mr. Brendan Brennan. And we are putting in place, I think I sort of alluded to earlier in the call, a number of things that we're doing to promote people in a more timely manner to bring in new graduates to really put a focus on bringing in new -- on people who are more in the sort of clinical trial assistant role and to train them and all that good stuff. They recognize we're in a dynamic industry. Strong cash generation resulting in a record net cash position of $494 million. . And we've seen a little bit of an uptick we're addressing it. But really, it's an opportunity to very much expand the capabilities of our clinical research network, if you like. Thank you, Brendan, and good day, everyone. Or are you able to pass higher labor costs along in your bids? All at ICON. Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share exclude amortization, stock compensation, foreign exchange gains and losses and transaction-related / integration-related adjustments. As you know, we're thinking about 14% for the long run. . You have a lot of partnerships. And one for Brendan. They did transition and start adding in full bookings about a year ago, but I'm curious if you would have that number at hand, just for comparable purposes for those of us who are tracking PRA in the past? Strong operational performance in the third quarter drove constant dollar organic revenue growth of 7.4%, with excellent cost management and strong utilization driving adjusted EBITDA growth of 16.9% year over year, and adjusted earnings per share growth of 17.5% over third quarter 2021. Sure, Elizabeth. Days sales outstanding reduced to 31 days from 57 days at December 31, 2020 on a comparable basis. Full year net business wins of $9,450 million; a net book to bill of 1.22. This compares with a net accounts receivable balance of $465.6 million at March 31, 2021. A recording will also be available on the website for 90 days following the call. For a presentation of the most directly comparable GAAP financial measures, please refer to the press release statement headed condensed consolidated statements of operations U.S. GAAP unaudited. Jonathan Curtain, VP, Corporate Finance & Investor Relations +35312912000 [email protected] Media enquiries: ICON. ICON purchased a majority shareholding in MeDiNova on May 23, 2019. Demand was also very high for our high-yield bond with subscriptions of over $3 billion, helping us to secure a rate of just 2.875%. ICON We said we'd start off it in around the ballpark of 17% and work our way down from that, Eric. Flaticon, the largest database of free icons. Reported income from operations in the quarter was $119.9 million or 15.8% of revenue compared to $115.3 million or 15.9% of revenue for Quarter 4 2019. And then maybe just one on kind of the COVID work and you talked a lot about it. Successful decentralized trials require mobile site and patient-centric technology to support telemedicine, site resources to ease the investigator and patient burden, in-home services to patients, central labs to process and manage testing and also direct-to-patient capabilities to enable drug distribution and management. Please ask your question. Adjusted net income1 attributable to the Group was $968.7 million resulting in an adjusted diluted earnings per share1 of $11.75 compared to $9.65 per share for the equivalent prior year period. That's right -- theythink these 10stocks are even better buys. At December 31, 2022, the Group had cash and cash equivalents of $288.8 million, compared to cash and cash equivalents of $609.2 million at September30, 2022 and $752.2 million at December31, 2021. All at ICON. . Data Provided by Refinitiv. And as it seems to be a bit of a sigmoidal curve, does that makes sense? Adjusted net income per Ordinary Share attributable to the Group: Weighted average number of Ordinary Shares outstanding: Net income per Ordinary Share attributable to the Group: ICON plc We have a very, I believe, a compelling offering in that space. Reported revenue for Quarter 4 was $760.2 million. Not to hand, Eric. In addition, we have seen growing interest from sponsors in clinical trial tokenization. suit small local trials or large global programs. So we will stay focused on that in that interim period. Download 1767 free Investor relations Icons in All design styles. In connection with the proposed transaction, ICON expects to file a registration statement on Form F-4 with the SEC containing a preliminary prospectus of ICON that also constitutes a preliminary proxy statement of each of ICON and PRA. ICON plc 20-F 2020.PDF 1.8 MB. development and commercialisation, and can be adapted to It's great to hear about the revenue synergies and then kind of the hit rate. So I think that's broadly where it's at. With headquarters in Dublin, Ireland, ICON employed approximately 38,330 employees in 142 locations in 53 countries as at December 31, 2021. Adjusted earnings per share attributable to the Group (Non-GAAP) has been computed by dividing non-GAAP net income attributable to the Group by the weighted average number of shares outstanding. I don't have the detail for PRA at this stage. Our top customer represented 12.7% of revenue for the quarter compared with 12.1% in quarter two 2020. Not that there's not follow-on work, there's no cliff, but the sort of -- I think we've hit the peak there. Full year revenue was $5,480.8 million. Before moving to Q&A, I would again like to welcome our PRA colleagues to the new ICON and thank all of our teams for all their hard work and commitment during the quarter. But it's certainly been a very positive environment from COVID work. But I think that was certainly a factor for the revenues on the PRA side of things as it was for ICON. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. The final structure will allow us to maximize repayable debt to do that quickly. In addition, as announced, ICON and PRA Health Services (PRA) have entered into a definitive merger agreement. And that's -- we can't complain about the business development wins being strong and attrition being high at the same time, you have to probably take one with the other as well. Investor Relations | Datadog And I think we're seeing that as we come out of the pandemic with the vaccine, the patients who are in the vaccine portfolios, the ability to have a look at that data on an ongoing basis would be extremely valuable and -- is extremely valuable. During the year the company recorded a charge of $18.1 million in relation to restructuring costs. Full year net business wins of $6,958 million; a net book to bill of 1.27. Yes, we're feeling like we're making good progress on the real-world data. design styles for web or mobile (iOS and Android) design, marketing, or developer projects. ICON exercised its call on the outstanding shares in MeDiNova and derecognized the non-controlling interest effective from March 2020. Contact: Investor Relations +1 888 381 7923 or Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. This compared to 15% last quarter and 12.1% in the comparable quarter last year. Quarter 3 revenue of $1,942.4 million representing an increase of 3.9% on prior year adjusted revenue and 7.4% on a constant currency organic basis. ICON CARES is our commitment to making a positive impact on our people, environment and our community. Net debt balance of $4.4 billion with net debt to adjusted EBITDA ratio of 2.9x. Obviously, we are the larger company by market cap. Or is that more of a normalized comment beyond the bump of COVID trial work? Alexander Yearley Draper -- Truist Securities -- Analyst. Adjusted operating income in the quarter -- in quarter two was $132.9 million, a margin of 15.3%. This represents a year-on-year increase of 12.7%. Full year 2021 revenue guidance in the range of $3,200 - $3,300 million, a year over year increase of 14.4% - 18.0%. I think that's probably more the latter, Dan. Your next question comes from the line of Luke Sergott from Barclays. As I'm trying to think about framing 2022, I know you said there's no COVID cliff, but there's a tough comp from COVID vaccine trial. Our mission is to help clients accelerate the development of provides analysis and key insights on these challenges, with In the first six months as the new ICON, we have already made significant progress against our initial transaction targets, with a $500m debt repayment on our Term Loan B facility, and an expectation to realize approximately 50% cost synergies by the end of 2022. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. So I think there are a lot of moving parts going on in this -- in the labor market as such. GAAP revenue for Quarter 4 was $1,885.1 million. Consequently, net awards in the quarter were a record $1.1 billion resulting in a net book-to-bill of 1.27 times and a trailing 12-month net book-to-bill of 1.34 times. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. 10 stocks we like better thanICONWhen our award-winning analyst team hasa stock tip, it can pay to listen. through a number of high-profile industry awards. But also the good models that we have for running our support services in terms of the efficiency of our enterprisewide systems and the onshore/offshore models that we've had in the organization for quite some time now. These are certainly exciting times for us at the new ICON and we're pleased to have delivered another strong quarter demonstrating continuing progress and representing a strong platform for future growth. Next question from the line of David Windley from Jefferies. Just a question. So no huge surprise. Yes. And as we've seen -- PRA also have seen a similar sort of mid-teens sort of increases in their RFP. Full year reported revenue was $2,797 million.

Omega Healthcare Chennai, Minecraft Jump Switch, How Long Do Penfed Transfers Take, Articles I